알림

mobile background

Push the boundaries of fundus medical AI

DOCTOR EYE

Pushing the boundaries of medical AI with the DOCTOR EYE X-Series.

DOCTOR EYE

Pushing the boundaries of medical AI with the DOCTOR EYE X-Series.

X-EYE

Major vision-threatening ophthalmic conditions (Macular Degeneration, Diabetic Retinopathy, Epiretinal Membrane, Glaucoma)

X-ANGIO

Cerebral Aneurysm (A weakened, bulging spot in a brain artery that can cause a brain hemorrhage)

X-ADHD

ADHD (Attention Deficit Hyperactivity Disorder)

X-ECAS

Cerebrovascular Stenosis (Narrowing of the intracranial arteries or carotid arteries)

Rotating Border

DOCTOR EYE Solution

Assisting Diagnosis of 7 Conditions
with a Single Image

The DOCTOR EYE series comprises X-EYE, X-ANGIO, X-ADHD, and X-ECAS. Utilizing specialized AI analysis models designed for each condition, it screens for critical health risks, including diabetic retinopathy, macular degeneration, glaucoma, epiretinal membrane, cerebral aneurysm, ADHD, and cerebrovascular stenosis.

Captured fundus images are processed through condition-specific AI models to provide actionable insights for healthcare professionals. Rather than replacing a definitive diagnosis, DOCTOR EYE serves as a primary AI screening system for critical conditions, aiding in the early detection of patients who require further evaluation and specialized care.

ANGIO

Push the boundaries of fundus medical AI

*Expected Launch in 2027

Push the boundaries of fundus medical AI

Rotating Border

DOCTER EYE Solution

Assisting in Reading 7 Conditions
with a Single Capture

The DOCTER EYE series consists of X-EYE, X-ANGIO, X-ADHD, and X-ECAS. Through specialized AI analysis models for each condition, it screens for severe disease risks, including diabetic retinopathy, macular degeneration, glaucoma, epiretinal membrane, cerebral aneurysm, ADHD, and cerebrovascular stenosis.

Captured fundus images are processed through disease-specific AI models to deliver results directly to medical professionals. Rather than replacing a definitive diagnosis, DOCTER EYE is a first-line screening AI system for severe diseases that helps identify patients who require further examination and specialist care early on.

mobile background

TECHNOLOGY PLATFORM

PIEGENT

An integrated medical AI technology platform delivering safe and precise analytics

OASIS Biomarker Analysis

Biomarker analysis images

PLATFORM MODULE

OASIS

(Ophthalmic Analysis Segmentation Image System)

Advanced analysis technology for biomarkers including anatomical structures, blood vessels, and nerves within fundus images.
Accurately segments and analyzes features across 40 types of biomarkers in fundus photography.

✓ Anatomical Features
✓ Vascular Features
✓ Neural Features

MODULE / MODEL

CoMoE

(Cooperative Mixture-of-Experts)

Combines 40 biomarkers extracted via OASIS to extract optimized features for assessing risks of ocular diseases, brain disorders, and ADHD.

Risk Assessment Performance
for Ocular, Neurological, & ADHD Conditions

Ocular, Brain, & ADHD Risk Analysis

87%

REMEDIS Analysis

EXPLAINABLE AI

REMEDIS

Technology that highlights key focus areas analyzed by AI within fundus images using green markers.

✓ Visual Explanation
✓ Influential Region Heatmap

RESEARCH & DATA

Oculomics

World-leading Oculomics research conducted in collaboration with Seoul National University Hospital.

• Fundus Images: 1 Million
• MRI & CT Scans: 400,000

Oculomics Research Diagram

GLOBAL PARTNERSHIP

Cooperation

Piehealthcare collaborates with leading domestic and international institutions to advance technology development and research.

• Piehealthcare: Development of AI-based fundus & disease analysis technology
• Seoul National University Hospital: Joint clinical data research & validation
• University of Utah CMI: FDA collaboration with University of Utah CMI
• Georgia State University: Joint development of X-DEMENTIA-M

Piehealthcare

Seoul National University Hospital

University of Utah CMI

Georgia State University

mobile background

TECHNOLOGY PLATFORM

PIEGENT

Integrated Medical AI Platform Delivering Safe and Precise Analysis

OASIS Biomarker Analysis

Biomarker Analysis Images

PLATFORM MODULE

OASIS

(Ophthalmic Analysis Segmentation Image System)

Advanced biomarker analysis technology for fundus photography, covering anatomical structures, blood vessels, and neural features.
Identifies and analyzes 41 distinct biomarkers in fundus images.

Technology that combines 41 biomarkers analyzed by OASIS to identify the optimal combination for cerebral aneurysm analysis.

Anatomical Features
Vascular Features
Neural Features

MODULE / MODEL

CoMoE

(Cooperative Mixture-of-Experts)

Technology that combines 41 biomarkers analyzed by OASIS to determine the optimal combination for analyzing ocular diseases, brain disorders, and ADHD.

Risk Analysis Performance

Ocular, Brain, & ADHD Risk Analysis

87%

REMEDIS Analysis

EXPLAINABLE AI

REMEDIS

A technology that visualizes which regions of the fundus photograph the AI primarily focused on for analysis using green markers.

Visual Explanation
Influential Region Heatmap

Retinal Disease Diagnosis

REMEDIS

A Clinical AI Framework for Retinal Disease Diagnosis with Explainable Fundus Image Analysis

This paper introduces a system that diagnoses 4 major retinal diseases through real-time fundus image analysis in a SaaS-based cloud environment
and presents visual diagnostic rationale for AI using Grad-CAM technology.

REMEDIS: A Clinical AI Framework for Retinal Disease Diagnosis with Explainable Fundus Image Analysis

Youngkyu Lee¹, Jinho Lee¹, Youngdae Jo¹, Jeongwoo Park¹,²

RESEARCH & DATA

Oculomics

This is the world's largest Oculomics research initiative, conducted in collaboration with Seoul National University Hospital.

Fundus Images: 1 Million
MRI, MRA, CT, US: 400,000

Oculomics Research Diagram

GLOBAL PARTNERSHIP

Cooperation

Piehealthcare collaborates with leading domestic and international institutions on technology development and research.

Piehealthcare: Development of AI-based fundus and disease analysis technology
Seoul National University Hospital: Joint clinical data research and validation
University of Utah CMI: Collaboration with FDA and University of Utah CMI
Georgia State University: Joint development of X-DEMENTIA-M

Piehealthcare

Seoul National University Hospital

University of Utah CMI

Georgia State University

mobile background

Piehealthcare : AI Software

DOCTER EYE AI

DOCTER EYE X-EYE is an AI software solution that analyzes retinal fundus images within seconds to detect major ophthalmic conditions, including macular degeneration, diabetic retinopathy, glaucoma, and epiretinal membrane.

It empowers medical professionals to make faster, more accurate clinical decisions.

MFDS Approved (Approval No. 26-1)

DOCTER EYE X-EYE: How to Use

Fundus Image Acquisition

1

Fundus Photography

Autofocus & auto-capture
No darkroom required
Non-mydriatic imaging

DOCTER EYE Analysis

2

DOCTER EYE Analysis

AI analysis within seconds
Simultaneous screening for 4 major eye diseases

Suspected Condition Analysis Results

3

Suspected Condition Analysis

Comprehensive report on suspected conditions
Heatmap highlighting key AI focus areas

DOCTER EYE X-SERIES Milestones

2024

Development completed for DOCTER EYE X-EYE

2025

Initiated regulatory approval and commercialization for DOCTER EYE X-EYE; obtained MFDS Approval (Approval No. 26-1)

2026

Completed prototype development for DOCTER EYE X-ANGIO, DOCTER EYE X-ADHD, and DOCTER EYE X-ECAS

2027

Scheduled launch of DOCTER EYE X-ANGIO

mobile background

DOCTER EYE Retina Scan

DOCTER EYE X-EYE

Ophthalmic Disease AI Analysis - Commercialized & Advanced

DOCTER EYE X-ANGIO

Cerebral Aneurysm AI Analysis - Prototype Completed

DOCTER EYE X-ADHD

ADHD AI Analysis - Prototype Completed

DOCTER EYE X-ECAS

Cerebrovascular Stenosis AI Analysis - Prototype Completed

Piehealthcare : AI Software

DOCTER EYE AI

DOCTER EYE X-EYE is an AI software solution that detects major ophthalmic diseases, including macular degeneration, diabetic retinopathy, glaucoma, and epiretinal membrane, within seconds by analyzing retinal images captured with a fundus camera.

It empowers healthcare professionals to make faster and more precise clinical decisions.

MFDS Approved (Approval No. 26-1)

DOCTER EYE X-EYE : How to Use

Fundus Photography Image

1

Fundus Photography

Autofocus / Automatic capture
No darkroom required
Non-mydriatic approach

DOCTER EYE AI Analysis Image

2

DOCTER EYE Analysis

AI analysis within seconds
Simultaneous screening for 4 major eye diseases

Analysis Report Image

3

Analysis Results

Comprehensive report on suspected conditions
Heatmap highlighting key AI focus areas

DOCTER EYE AI SERIES

The DOCTER EYE AI series delivers rapid and precise diagnostic analysis across various medical fields.

Select a product to view detailed specifications and technical information.

DOCTER EYE X-EYE DOCTER EYE X-ANGIO DOCTER EYE X-ADHD DOCTER EYE X-ECAS

DOCTER EYE X-SERIES History

2024

Completed development of DOCTER EYE X-EYE

2025

Initiated regulatory approval and commercialization process for DOCTER EYE X-EYE and obtained MFDS Approval (Approval No. 26-1)

2026

Completed prototype development for DOCTER EYE X-ANGIO, DOCTER EYE X-ADHD, and DOCTER EYE X-ECAS

2027

Scheduled launch of DOCTER EYE X-ANGIO

mobile background

Real-Time Automated Analysis

Delivers results within seconds after fundus imaging to minimize patient wait times.
Flexible Device Compatibility

Integrates directly with DICOM standards and various fundus camera brands.
Automated Image Quality Control

Automatically evaluates image clarity to prevent diagnostic errors beforehand.

Diabetic Retinopathy

Detects early signs such as microaneurysms, retinal hemorrhages, and hard exudates.
Age-Related Macular Degeneration

Accurately identifies macular drusen accumulation and structural abnormalities.
Glaucoma

Measures the Cup-to-Disc (C/D) ratio and analyzes retinal nerve fiber layer defects.
Epiretinal Membrane

Detects fibrous membrane formation on the macular surface and retinal distortion.

Diagnostic Assistance

Enhances reading accuracy through analysis powered by ophthalmologist-validated data.
Streamlined Screening

Strengthens early disease detection and referral pathways across healthcare institutions.
Automated Report Generation

Provides clear patient consultations with visual reports highlighting lesion risk levels.
Reduced Waiting Time

Improves patient throughput by delivering rapid diagnostic analysis.

DOCTER EYE AI: Detecting Major Conditions Seconds After Imaging

Instant Automated Analysis: Delivers results within seconds of fundus photography, minimizing patient wait times.
Flexible Device Compatibility: Seamlessly integrates with DICOM standards and various fundus camera brands.
Automated Image Quality Validation: Automatically assesses image clarity to prevent diagnostic errors beforehand.

DOCTER EYE X-EYE is an AI software solution designed to integrate directly with fundus cameras. By analyzing fundus images in seconds, the system detects major condition presence—such as diabetic retinopathy, macular degeneration, glaucoma, and epiretinal membrane—to empower healthcare professionals in clinical decision-making.

2014

Apr Founded Piehealthcare

2024

Nov Acquired Medical Device GMP Certification

2025

Jan Acquired Venture Business Certification; Advanced DOCTER EYE X-EYE
Mar Participated in KIMES 2025; Unveiled DOCTER EYE X-EYE
Apr Acquired MAIN-BIZ and INNO-BIZ Certifications
Sep Awarded Ministerial Commendation at the MSS SME Business Innovation Contest; Signed MOU with KT
Oct Received Encouragement Award at Gyeonggi SME AI Transformation Best Practices Contest; Won Suwon Small & Medium Business Award (Business Innovation Category); Paper accepted for AAAI IAAI Track 2
Nov Selected for Korea Frontier (Batch 1); Invited to KTH Royal Institute of Technology as a Seoul National University recommended company
Dec Hosted AI Winter Internship with Ewha Womans University and Ajou University; Promoted R&D unit to Corporate R&D Center

2026

Jan Obtained MFDS Medical Device Manufacturing Approval for DOCTER EYE X-EYE; Participated in AAAI 2026; Established US Entity in California; Signed MOU with Ewha Womans University; Secured Seed Investment from Vector Investment and Vector Bio Private Investment Association
Mar Participated in KIMES 2026; Signed Main Sponsorship Agreement with Suwon FC
Apr Launched DOCTER EYE X-EYE; Selected as a Gyeonggi Star Company
May Participated in AI EXPO KOREA 2026 and WCIFIT 2026 in Chongqing; Successfully completed SNU AI CEO (4th Cohort) Company Visit; Acquired ISO 13485:2016 Certification
Jun Signed MOU with Kyungdongwon for regular support for children with developmental disabilities
Jul Acquired ISO 27017:2015 and ISO 27701:2025 Certifications; Participated in Manufacturing World Tokyo 2026
Aug Participated in KHF 2026

Registered

AI-Based Pharmaceutical Inventory Management and Method of Operating the Same

Application No.: 10-2025-0037931

Pending

AI-Based Apparatus and Method for Diagnosing Dementia

Application No.: 10-2024-0114766

Pending

Fundus Image-Based Apparatus and Method for Predicting Ophthalmic Diseases

Application No.: 10-2025-0033129

Pending

AI-Based Apparatus and Method for Measuring Carotid Intima-Media Thickness and Stenosis Stage

Application No.: 10-2025-0051915

Pending

Method and Apparatus for Assisting Cerebral Aneurysm Diagnosis Using Fundus Images

Application No.: 10-2025-0135358

Pending

Method and Apparatus for Assisting Cerebral Artery Stenosis Diagnosis Using Fundus Images

Application No.: 10-2025-0135359

Pending

Fundus Image-Based Employee Attendance and Health Management System and Method

Application No.: 10-2025-0146765

Pending

Apparatus, Method, and System for Providing Diagnostic Support Information for Cerebral Aneurysms

Application No.: 10-2026-0021647

Pending

Method and System for Distinguishing Between Normal and Severe Retinal Artery Stenosis

Pending

Method and System for Identifying Attention Deficit Hyperactivity Disorder (ADHD)

mobile background

AAAI 2026 Academic Achievement

IAAI Track 2 Selected Presented at AAAI 2026

Following the paper acceptance by an AAAI-affiliated journal in October 2025, Piehealthcare officially presented "REMEDIS", an AI-powered retinal diagnostics framework, at AAAI 2026 in Singapore.

Presented Paper / Framework REMEDIS: AI-Powered Retinal Diagnostics Framework

Key Technical Milestone Demonstrated Outstanding Zero-Shot Composed Image Retrieval (CIR) Performance

Suwon Small and Medium Business Award

Suwon Small and Medium Business Award

Commendation for Industrial R&D Advancement

2026.09.07 | Awarded by: Deputy Prime Minister and Minister of Science and ICT

Grand Prize, SME Management Innovation Contest

2025.09.04 | Awarded by: Minister of SMEs and Startups

Encouragement Award, Gyeonggi SME AI Transformation Best Practice Contest

2025.10.01

Suwon Small and Medium Business Award (Management Innovation)

2025.10.28

Selected for Korea Frontier 1st Cohort

2025.11.07

ISO 13485:2016 Medical Devices Quality Management System Certificate

ISO 13485:2016 Medical Devices Quality Management System Certificate

ISO 27701:2025 Privacy Information Management System Certificate

ISO 27701:2025 Privacy Information Management System Certificate

ISO 27017:2015 Information Security Management System Certificate

ISO 27017:2015 Information Security Management System Certificate

ISO 27001:2022 Information Security Management System Certificate

ISO 27001:2022 Information Security Management System Certificate

Registered

AI-Based Pharmaceutical Inventory Management and Method of Operating the Same

Application No.: 10-2025-0037931

Pending

AI-Based Apparatus and Method for Diagnosing Dementia

Application No.: 10-2024-0114766

Pending

Fundus Image-Based Apparatus and Method for Predicting Ophthalmic Diseases

Application No.: 10-2025-0033129

Pending

AI-Based Apparatus and Method for Measuring Carotid Intima-Media Thickness and Stenosis Stage

Application No.: 10-2025-0051915

Pending

Method and Apparatus for Assisting Cerebral Aneurysm Diagnosis Using Fundus Images

Application No.: 10-2025-0135358

Pending

Method and Apparatus for Assisting Cerebral Artery Stenosis Diagnosis Using Fundus Images

Application No.: 10-2025-0135359

Pending

Fundus Image-Based Employee Attendance and Health Management System and Method

Application No.: 10-2025-0146765

Pending

Apparatus, Method, and System for Providing Diagnostic Support Information for Cerebral Aneurysms

Application No.: 10-2026-0021647

Pending

Method and System for Distinguishing Between Normal and Severe Retinal Artery Stenosis

Pending

Method and System for Identifying Attention Deficit Hyperactivity Disorder (ADHD)

Submit

mobile background

mobile background